Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes - PubMed (original) (raw)
Comparative Study
Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes
J Fuhlendorff et al. Diabetes. 1998 Mar.
Abstract
The action of repaglinide, a novel insulin secretagogue, was compared with the sulfonylurea glibenclamide with regard to the hypoglycemic action in vivo, binding to betaTC-3 cells, insulin secretion from perifused mouse islets, and capacity to stimulate exocytosis by direct interaction with the secretory machinery in single voltage-clamped mouse beta-cells. Two binding sites were identified: a high-affinity repaglinide (KD = 3.6 nmol/l) site having lower affinity for glibenclamide (14.4 nmol/l) and one high-affinity glibenclamide (25 nmol/l) site having lower affinity for repaglinide (550 nmol/l). In contrast to glibenclamide, repaglinide (in concentrations as high as 5 micromol/l) lacked the ability to enhance exocytosis in voltage-clamped beta-cells. Repaglinide was more potent than glibenclamide in stimulating insulin release from perifused mouse islets (EC50 29 vs. 80 nmol/l). The greater potency of repaglinide in vitro was paralleled by similar actions in vivo. The ED50 values for the hypoglycemic action were determined to be 10.4 and 15.6 microg/kg after intravenous and oral administration, respectively. The corresponding values for glibenclamide were 70.3 microg/kg (intravenous) and 203.2 microg/kg (oral). Further, repaglinide (1 mg/kg p.o.) was effective (P < 0.001) as an insulin-releasing agent in a rat model (low-dose streptozotocin) of type 2 diabetes. These observations suggest that the insulinotropic actions of repaglinide and glibenclamide in vitro and in vivo are secondary to their binding to the high-affinity repaglinide site and that the insulinotropic action of repaglinide involves both distinct and common cellular mechanisms.
Similar articles
- Pancreatic beta-cell K(ATP) channel activity and membrane-binding studies with nateglinide: A comparison with sulfonylureas and repaglinide.
Hu S, Wang S, Fanelli B, Bell PA, Dunning BE, Geisse S, Schmitz R, Boettcher BR. Hu S, et al. J Pharmacol Exp Ther. 2000 May;293(2):444-52. J Pharmacol Exp Ther. 2000. PMID: 10773014 - Compared to glibenclamide, repaglinide treatment results in a more rapid fall in glucose level and beta-cell secretion after glucose stimulation.
Abbink EJ, van der Wal PS, Sweep CG, Smits P, Tack CJ. Abbink EJ, et al. Diabetes Metab Res Rev. 2004 Nov-Dec;20(6):466-71. doi: 10.1002/dmrr.474. Diabetes Metab Res Rev. 2004. PMID: 15386823 Clinical Trial. - Pharmacology of the meglitinide analogs: new treatment options for type 2 diabetes mellitus.
Malaisse WJ. Malaisse WJ. Treat Endocrinol. 2003;2(6):401-14. doi: 10.2165/00024677-200302060-00004. Treat Endocrinol. 2003. PMID: 15981944 Review. - Mechanism of action of a new class of insulin secretagogues.
Malaisse WJ. Malaisse WJ. Exp Clin Endocrinol Diabetes. 1999;107 Suppl 4:S140-3. doi: 10.1055/s-0029-1212170. Exp Clin Endocrinol Diabetes. 1999. PMID: 10522840 Review.
Cited by
- The aqueous extract of Withania coagulans fruit partially reverses nicotinamide/streptozotocin-induced diabetes mellitus in rats.
Shukla K, Dikshit P, Shukla R, Gambhir JK. Shukla K, et al. J Med Food. 2012 Aug;15(8):718-25. doi: 10.1089/jmf.2011.1829. Epub 2012 Jun 25. J Med Food. 2012. PMID: 22846078 Free PMC article. - Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL, Figgitt DP. Plosker GL, et al. Pharmacoeconomics. 2004;22(6):389-411. doi: 10.2165/00019053-200422060-00005. Pharmacoeconomics. 2004. PMID: 15099124 Review. - Association analysis of SLC30A8 rs13266634 and rs16889462 polymorphisms with type 2 diabetes mellitus and repaglinide response in Chinese patients.
Huang Q, Yin JY, Dai XP, Wu J, Chen X, Deng CS, Yu M, Gong ZC, Zhou HH, Liu ZQ. Huang Q, et al. Eur J Clin Pharmacol. 2010 Dec;66(12):1207-15. doi: 10.1007/s00228-010-0882-6. Epub 2010 Aug 31. Eur J Clin Pharmacol. 2010. PMID: 20809084 - Safety Assessment and Pain Relief Properties of Saffron from Taliouine Region (Morocco).
Ait Tastift M, Makbal R, Bourhim T, Omari Z, Isoda H, Gadhi C. Ait Tastift M, et al. Molecules. 2022 May 23;27(10):3339. doi: 10.3390/molecules27103339. Molecules. 2022. PMID: 35630819 Free PMC article. - Pancreatic regulation of glucose homeostasis.
Röder PV, Wu B, Liu Y, Han W. Röder PV, et al. Exp Mol Med. 2016 Mar 11;48(3):e219. doi: 10.1038/emm.2016.6. Exp Mol Med. 2016. PMID: 26964835 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical